Quest Diagnostics (DGX) exhibited stable share performance over a year, despite a volatile healthcare market. It continues its innovative stride in preventive health through a partnership with Shield. Despite this, Barclays maintains an Equal-Weight recommendation, even as DGX's stock thrives for a strong market position and a year of growth. DGX made significant strides like collaborating with Epic for industry-first improvement in lab tests, entering joint ventures and making key acquisitions. Among others, its acquisition include clinical testing assets from Fresenius Medical Care that broadens Guardant Health’s blood-based screening test in the US. Bold partnership with WHOOP directly involves DGX in consumer health thus enriching testing options. Its various test offers include the Oropouche Virus and Alzheimer's disease, implications of its unrelenting research & development performance.Quest also set to treat 200,000 dialysis patients annually with its takeover of Fresenius Labs. Expansion of consumer health reach after partnerships, like with WHOOP, boosted the DGX stock, and the DGX stock surge is forecasted to continue with its ongoing innovative efforts. Its visionary approach informs the development of tests for precision medicine and the bold step to launch health coaching on its website. However, amidst the innovative actions of DGX, it still had to deal with regulatory worries like tariff and Medicare Act risks.
Quest Diagnostics DGX News Analytics from Tue, 03 Dec 2024 08:00:00 GMT to Sat, 04 Oct 2025 18:30:06 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 5
